Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program
An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of interv
| Condition(s) | Adverse Drug Event |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided. |
| Who can participate | Inclusion Criteria: Patients with a recent diagnosis and who are to be or are being treated according to usual clinical practice, who meet the criteria to participate in the study, read the corresponding information sheet, sign informed consent and agree to participate, provided they meet the following inclusion criteria: General criteria for all patients: * Age ≥ 18 years. In case of minors, they may be included, under the following assumptions: * If the minor is under 12 years of age, participation will require the consent and signature of the informed consent document by both parents (or their guardian). * If the minor is between 12 and 16 years of age, a proxy informed consent form will be provided and signed by both parents (if both parents are present at the time of the interview) or |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Complejo Hospitalario Universitario de Badajoz |
| Locations | Badajoz, Spain |
| Start date | 2021-05-26 |
| NCT ID | NCT06607445 |
| Official listing | https://clinicaltrials.gov/study/NCT06607445 |